MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma

International Journal of Biological Sciences

Volumn 10, Issue 7, 2014, Pages 733-745

  Dang, Zheng ^a,b   Xu, Wei Hua ^a   Lu, Peng ^a,c   Wu, Nan ^a   Liu, Jie ^a   Ruan, Bai ^a   Zhou, Liang ^d   Song, Wen Jie ^a   Dou, Ke Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b LANZHOU GENERAL HOSPITAL   (China)

^c Department of Internal Medicine   (China)

^d The 155 Central Hospital of PLA   (China)

Author keywords

Apoptosis; Bmi1; Cell proliferation; MiR 135a; Pancreatic ductal adenocarcinoma

Indexed keywords

BMI1 PROTEIN; BMI1 PROTEIN, HUMAN; MICRORNA; MIRN135 MICRORNA, HUMAN;

ADENOCARCINOMA; APOPTOSIS; BIOLOGY; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PANCREAS CARCINOMA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 1;

EID: 84903302645     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.8097     Document Type: Article

References (52)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
3. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009; 60: 167-179.
4. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27: 5848-5856.
5. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002; 99: 15524-15529.
6. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006; 103: 2257-2261.
7. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008; 26: 462-469.
8. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105: 10513-10518.
9. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-838.
10. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 2006; 25: 6163-6169.
11. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008; 47: 897-907.
12. Cheng AM, Byrom MW, Shelton J, et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005; 33: 1290-1297.
13. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447: 1130-1134.
14. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007; 26: 4442-4452.
15. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009; 2: 807-813.
16. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007; 120: 1046-1054.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 2001; 25: 402-408.
18. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA. 2008; 105: 2415-2420.
19. Zhou W, Li X, Liu F, et al. MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. Acta Biochim Biophys Sin (Shanghai). 2012; 44: 838-846.
20. Wu H, Huang M, Cao P, et al. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther. 2012; 13: 281-288.
21. Navarro A, Diaz T, Martinez A, et al. Regulation of JAK2 by miR-135a: prognostic impact in classic hodgkin lymphoma. Blood. 2009; 114: 2945-2951.
22. Yamada Y, Hidaka H, Seki N, et al. Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci. 2013; 104: 304-312.
23. Yu Q, Su B, Liu D, et al. Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549. Oligonucleotides. 2007; 17: 327-335.
24. Guo WJ, Zeng MS, Yadav A, et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 2007; 67: 5083-5089.
25. Meng XX, Liu WH, Liu DD, et al. Construction of antisense Bmi-1 expression plasmid and its inhibitory effect on k562 cells proliferation. Chin Med J (Engl) 2005; 118: 1346-1350.
26. Song W, Tao K, Li H, et al. Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci. 2010; 101: 1754-1760.
27. Xiao J, Deng C. Knockdown of Bmi-1 impairs growth and invasiveness of human gastric carcinoma cells. Oncol Res. 2009; 17: 613-620.
28. Qin L, Zhang X, Zhang L, et al. Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 2008; 371: 531-535.
29. Guo BH, Feng Y, Zhang R, et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011; 10: 10.
30. Nagao Y, Hisaoka M, Matsuyama A, et al. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma. Mod Pathol. 2012; 25: 112-121.
31. Zhao WG, Yu SN, Lu ZH, et al. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010; 31: 1726-1733.
32. Gramantieri L, Fornari F, Callegari E, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008; 12: 2189-2204.
33. Nakata K, Ohuchida K, Mizumoto K, et al. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011; 150: 916-922.
34. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11: 1487-1495.
35. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003; 3: 900-911.
36. Wu S, Lin Y, Xu D, et al. MiR-135a functions as a selective killer of malignant glioma. Oncogene. 2012; 31: 3866-3874.
37. Tang WW, Wan GP, Wan YC, et al. Effects of miR-135a on HOXA10 expression, proliferation and apoptosis of ovarian cancer cells. Zhonghua Fu Chan Ke Za Zhi. 2013; 48: 364-369.
38. Dang CV, O'Donnell KA, Zeller KI, et al. The c-Myc target gene network. Semin Cancer Biol. 2006; 16: 253-264.
39. Chariot A, Gielen J, Merville MP, et al. The homeodomain-containing proteins: an update on their interacting partners. Biochem Pharmacol. 1999; 58: 1851-1857.
40. Chen Y, Zhang J, Wang H, et al. miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 2012; 12: 111.
41. Liu S, Guo W, Shi J, et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 2012; 56: 389-396.
42. Liu K, Wang G, Ding H, et al. Downregulation of metastasis suppressor 1 (MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer. 2010; 10: 428.
43. Parr C, Jiang WG. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer. 2009; 45: 1673-1683.
44. Ma S, Guan XY, Lee TK, et al. Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. Hum Pathol. 2007; 38: 1201-1206.
45. Saini S, Majid S, Yamamura S, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011; 17: 5287-5298.
46. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003; 423: 255-260.
47. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003; 423: 302-305.
48. Sawa M, Yamamoto K, Yokozawa T, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol. 2005; 82: 42-47.
49. Yang J, Chai L, Liu F, et al. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci USA. 2007; 104: 10494-10499.
50. Raaphorst FM. Self-renewal of hematopoietic and leukemic stem cells: a central role for the polycomb-group gene Bmi-1. Trends Immunol. 2003; 24: 522-524.
51. Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem. 1995; 270: 18195-18197.
52. Zupkovitz G, Grausenburger R, Brunmeir R, et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol. 2010; 30: 1171-1181.